Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Neoplasm Metastasis 1HRD Cancer 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 15Etoposide 13atezolizumab 9Topotecan 8durvalumab 7Specimen Handling 7PM 01183 6Cisplatin 5pembrolizumab 4Magnetic Resonance Spectroscopy 4Irinotecan 4Injections 3Biopsy 3berzosertib 2Nivolumab 2Fulvestrant 2Drug Therapy 2AMG 757 2tremelimumab 1trastuzumab deruxtecan 1toripalimab 1tazemetostat 1palbociclib 1olaparib 1lenvatinib 1fludarabine 1enzalutamide 1cabozantinib 1budigalimab 1arginine decarboxylase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × berzosertib × 30 days × Clear all
NCT03896503 2026-06-01

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

National Cancer Institute (NCI)

Phase 2 Active not recruiting
104 enrolled 22 charts
Thoracic

Small Cell Lung Carcinoma

NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
66 enrolled
GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡